维布妥昔单抗在复发/难治性霍奇金淋巴瘤中的免疫脱靶效应
研究纳入15例连续复发/难治性霍奇金淋巴瘤患者,评估维布妥昔单抗单药治疗对外周血调节性T细胞、髓源性抑制细胞亚群及血清精氨酸酶-1的影响。中位4个周期后总缓解率为47%,完全代谢缓解4例(27%)。维布妥昔单抗减少三种MDSC亚型绝对数和血清精氨酸酶-1水平,并恢复调节性T细胞功能。
要点
- 中位4个BV周期后总缓解率47%,完全代谢缓解4例(27%)。
- 维布妥昔单抗减少三种MDSC亚型绝对数及血清精氨酸酶-1水平。
- 基线血清精氨酸酶-1≥200 ng/ml者36个月无进展生存较差。
核心结论
- 维布妥昔单抗在复发/难治性霍奇金淋巴瘤中具有脱靶免疫效应,可能解释其深度且持久的临床疗效。
研究设计与样本
- 研究在外周血中评估15例连续复发/难治性霍奇金淋巴瘤患者,检测调节性T细胞、髓源性抑制细胞亚群及血清精氨酸酶-1。
主要发现
- 中位4个维布妥昔单抗周期后,总缓解率(完全缓解+部分缓解)为47%,完全代谢缓解4例(27%)。
- 维布妥昔单抗减少三种MDSC亚型绝对数及血清精氨酸酶-1水平。
- 基线血清精氨酸酶-1≥200 ng/ml者36个月无进展生存较血清精氨酸酶-1低者差。
- 维布妥昔单抗治疗后调节性T细胞绝对数增加,与是否达到代谢缓解无关,CD30+调节性T细胞显著减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hodgkin Lymphoma (HL) is associated with deep microenvironment re-shaping and myeloid dysfunction. Given that only limited data are available regarding the role of Brentuximab Vedotin (BV) as single agent in transplant-naive relapsed/refractory (R/R) patients and its off-target effects on immune system, we evaluated the amount of regulatory T-cells (T-regs), myeloid-derived suppressor cells (MDSC) subpopulations, and their functional marker, serum arginase-1 (s-Arg-1), in peripheral blood of 15 consecutive R/R HL patients. After a median of four BV cycles, the overall response rate (complete response + partial response) was 47%, with 4 (27%) complete metabolic remissions. BV reduced the absolute number of three MDSC subtypes and s-Arg-1 levels. Patients with baseline s-Arg-1 ≥200 ng/ml had inferior progression-free survival at 36 months compared to those with low s-Arg-1. T-regs dysfunction was recovered by BV: absolute T-regs count was increased after treatment with BV, independently of metabolic response achieved, with a significant reduction of CD30+ T-regs. Our data disclose off-target effects of BV in the microenvironment that could explain its deep and durable clinical efficacy.
引用
- Romano A, Parrinello NL, Chiarenza A, et al. Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. Br J Haematol. 2019. PMID: 30768678. doi:10.1111/bjh.15801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。